Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
PGEN Precigen	$1.42 -5.3%	$1.44	$0.65 ▼ $2.17	$442.77M	1.84	1.38 million shs	1.71 million shs
SIGA Siga Technologies	$6.44 +0.6%	$6.03	$4.95 ▼ $12.83	$457.22M	0.93	723,601 shs	317,118 shs
VERV Verve Therapeutics	$11.21 +0.4%	$5.89	$2.86 ▼ $11.41	$995.73M	1.67	2.40 million shs	3.34 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PGEN Precigen	-5.33%	-4.70%	+3.65%	-13.41%	-14.97%
SIGA Siga Technologies	+0.63%	+0.31%	+8.97%	+15.62%	-12.62%
VERV Verve Therapeutics	+0.36%	+0.81%	+157.11%	+112.31%	+114.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	3.7237 of 5 stars	3.5	1.0	0.0	4.7	1.1	1.7	0.6
SIGA Siga Technologies	1.7527 of 5 stars	0.0	3.0	0.0	0.0	0.8	0.8	3.1
VERV Verve Therapeutics	2.9976 of 5 stars	4.2	1.0	0.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPNT Opiant Pharmaceuticals	0.00	N/A	N/A	N/A
PGEN Precigen	3.00	Buy	$6.00	322.54% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
VERV Verve Therapeutics	2.38	Hold	$14.75	31.58% Upside

Current Analyst Ratings Breakdown

Latest OPNT, SIGA, VERV, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/15/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $24.00
4/15/2025	VERV Verve Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/15/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $39.00
4/14/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $25.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
PGEN Precigen	$3.92M	106.93	N/A	N/A	$0.13 per share	10.92
SIGA Siga Technologies	$138.72M	3.32	$0.84 per share	7.65	$3.02 per share	2.13
VERV Verve Therapeutics	$32.33M	30.91	N/A	N/A	$5.83 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.61	5.15	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest OPNT, SIGA, VERV, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest OPNT, SIGA, VERV, and PGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA Siga Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
PGEN Precigen	N/A	3.53	3.53
SIGA Siga Technologies	N/A	8.40	6.28
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OPNT Opiant Pharmaceuticals	42.39%
PGEN Precigen	33.51%
SIGA Siga Technologies	55.40%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
OPNT Opiant Pharmaceuticals	25.15%
PGEN Precigen	47.10%
SIGA Siga Technologies	1.95%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

OPNT, SIGA, VERV, and PGEN Headlines

Recent News About These Companies

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24 at 10:42 PM | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24 at 5:41 PM | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24 at 3:08 AM | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23 at 2:58 AM | insidermonkey.com

Research Analysts Offer Predictions for VERV Q2 Earnings

June 21, 2025 | americanbankingnews.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Lifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC Wainwright

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial Group

June 20, 2025 | americanbankingnews.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19, 2025 | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18, 2025 | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18, 2025 | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18, 2025 | marketbeat.com

Verve Therapeutics' (VERV) "Hold" Rating Reiterated at Jefferies Financial Group

June 18, 2025 | marketbeat.com

Lock In The 81.5% Run - Initiating Verve With A Sell

June 18, 2025 | seekingalpha.com

Verve Therapeutics (NASDAQ:VERV) Sets New 12-Month High - Here's Why

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPNT, SIGA, VERV, and PGEN Company Descriptions

Opiant Pharmaceuticals NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Precigen NASDAQ:PGEN

$1.42 -0.08 (-5.33%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+1.76%)

As of 06/25/2025 07:57 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Siga Technologies NASDAQ:SIGA

$6.44 +0.04 (+0.63%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$6.47 +0.03 (+0.47%)

As of 06/25/2025 06:20 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Verve Therapeutics NASDAQ:VERV

$11.21 +0.04 (+0.36%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$11.19 -0.02 (-0.14%)

As of 06/25/2025 07:55 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time